HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Product Liability

This article was originally published in The Rose Sheet

Executive Summary

Product Liability: Senate fails twice to invoke cloture May 4 on substitute amendment offered by Sen. Slade Gorton (R-WA) to the "Product Liability Fairness Act" (HR 956). The substitute is a heavily amended version of the original Gorton-Rockefeller bill (S 565). The first vote (46-53) to limit debate fell short of the necessary 60 votes by a wide margin, with two Democrats, Sens. Joseph Lieberman (CT) and James Exon (NE), breaking ranks. In the second vote (47-52), Republican Strom Thurmond (R-SC) switched his vote in favor of cloture. Senate majority leader Robert Dole (R-KS) indicated before the votes that in the event of no cloture, another Gorton-Rockefeller amendment would be considered as a substitute; GOP leadership indicated that the measure is likely to be considered again during the week of May 8...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001599

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel